0001104659-23-087887.txt : 20230804
0001104659-23-087887.hdr.sgml : 20230804
20230804163936
ACCESSION NUMBER: 0001104659-23-087887
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20230802
FILED AS OF DATE: 20230804
DATE AS OF CHANGE: 20230804
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Stephan Dietrich A
CENTRAL INDEX KEY: 0001774588
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-35963
FILM NUMBER: 231144576
MAIL ADDRESS:
STREET 1: 213 SMITHFIELD ST
CITY: PITTSBURGH
STATE: PA
ZIP: 15222
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: NeuBase Therapeutics, Inc.
CENTRAL INDEX KEY: 0001173281
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 465622433
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 350 TECHNOLOGY DRIVE
CITY: PITTSBURGH
STATE: PA
ZIP: 15219
BUSINESS PHONE: 412-763-3350
MAIL ADDRESS:
STREET 1: 350 TECHNOLOGY DRIVE
CITY: PITTSBURGH
STATE: PA
ZIP: 15219
FORMER COMPANY:
FORMER CONFORMED NAME: Ohr Pharmaceutical Inc
DATE OF NAME CHANGE: 20090819
FORMER COMPANY:
FORMER CONFORMED NAME: BBM HOLDINGS, INC.
DATE OF NAME CHANGE: 20070402
FORMER COMPANY:
FORMER CONFORMED NAME: PRIME RESOURCE INC
DATE OF NAME CHANGE: 20020513
4
1
tm2322948-1_4seq1.xml
OWNERSHIP DOCUMENT
X0508
4
2023-08-02
0
0001173281
NeuBase Therapeutics, Inc.
NBSE
0001774588
Stephan Dietrich A
C/O 350 TECHNOLOGY DRIVE, FOURTH FLOOR
PITTSBURGH
PA
15219
1
1
1
0
Founder and CEO
0
Common Stock
2023-08-02
4
M
0
93234
0.022
A
93234
D
Common Stock
7650
D
Common Stock
73588
D
Common Stock
63690
I
See footnote
Stock option (right to buy)
0.022
2023-08-02
4
M
0
93234
0
D
2019-07-12
2023-12-31
Common Stock
93234
0
D
Shares held by the reporting person as a tenant by the entirety with his spouse.
These shares are held in an irrevocable trust in which the spouse of the reporting person is the investment trustee, and the spouse and the descendants of the reporting person are its beneficiaries, and another irrevocable trust in which the reporting person is the investment trustee, and the reporting person and the descendants of the reporting person's spouse are its beneficiaries.
Effective on June 14, 2023, NeuBase Therapeutics, Inc. conducted a reverse stock split at a ratio of 1-for-20 (the "Reverse Split"). The numbers of shares reported herein reflect the numbers of shares after the Reverse Split.
Reflects stock options under NeuBase Therapeutics, Inc.'s 2018 Equity Incentive Plan.
/s/ Todd P. Branning
2023-08-04